Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of Intravenous Human Normal Immune Globulin (IGIV) 10% in Adult Patients With Stiff Person Syndrome

NCT07552987 is registered in ClinicalTrials.gov with Kedrion S.p.A. as lead sponsor.

NCT NCT07552987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of Intravenous Human Normal Immune Globulin (IGIV) 10% in Adult Patients With Stiff Person Syndrome
Lead sponsor
Kedrion S.p.A.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
July 31, 2028
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stiff person syndrome